The benefits and the red flags
ZUPREME-1 · Completed March 7, 2026 · Published September 29, 2026
What happened when the trial became larger?
Subject One arrives carrying a gold frame for the result. Doctide sets down a second frame, the same size, for the safety findings. The visitor rearranges the wall until both fit. “Neither goes behind the curtain,” Doctide says. Subject One puts the curtain away.
What changes here
The weight result and the serious harms belong on the same page. [1]
Read the study details & dates
Phase 2 in adults without type 2 diabetes
The completed randomized, double-blind trial compared weekly subcutaneous petrelintide with placebo plus lifestyle measures in adults with obesity, or overweight with hypertension/dyslipidemia. There were 493 randomized participants; 485 received treatment. [3] [1]
Keep the analysis attached to the number
Mean weight reduction was 7.9–9.8% across active groups versus 1.7% with placebo. The efficacy estimand assumed continued treatment without other weight-management therapy; repeated-measures modeling assumed missing-at-random data. Nausea occurred in 20% versus 6%. [1] [2]
What this does not establish
Zealand funded the study. There was no active-drug comparator; 86% of participants were White. These results cannot establish superiority to semaglutide or tirzepatide, or long-term safety.
Original sources
- Garvey et al. — ZUPREME-1, Lancet Diabetes & Endocrinology; published September 29, 2026
- Public copy of the ZUPREME-1 article and appendix (safety text on article page 10)
- ClinicalTrials.gov — NCT06662539, ZUPREME-1
Reviewed October 20, 2026: original article text and safety table in a publicly accessible copy, cross-checked against PubMed and registry. The publisher page was inaccessible; we do not claim a complete audit of every appendix analysis.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story